期刊文献+

唑来膦酸治疗恶性肿瘤骨转移疼痛疗效观察 被引量:4

Therapeutic observation of Zoledronic acid in the treatment of pain caused by metastatic bone tumors
下载PDF
导出
摘要 目的观察唑来膦酸对恶性肿瘤骨转移疼痛的治疗效果和安全性。方法对47例恶性肿瘤骨转移患者用唑来膦酸4mg加入生理盐水100ml静脉滴注,滴注时间30~40min,间隔4周重复给药1次,连续给药2次后评价疗效和不良反应。结果总有效率为80.8%(38/47),其中显效25.5%(12/47),有效55.3%(26/47);不良反应为头晕、乏力、发热及一过性骨痛等,发生率较低。结论唑来膦酸治疗恶性肿瘤骨转移疼痛有良好疗效,不良反应较轻,患者易于耐受,值得临床推广使用。 Objective To observe the therapeutic effect and safety of zoledronic acid in the treatment of patients with pain caused by metastatic bone tumors. Methods 47 patients with pain caused by metastatic bone tumors were treated with zoledronic acid 4mg +0.9% NS 100ml intravenous infusion in 30 -40 minites, The treatment was repeated at 4 weeks intervals, the effect and toxicity was assessed after continuous twice treatment. Results The overall response rate of zoledronie acid was 80.8% (38/47). excellent rate was 25.5% (12/47) ,effective was 55.3% (26/47). The main adverse effects were dizziness,hypodynamia, pyrexia and temporarily ostealgia, their incidence rate is lower. Conclusion Zoledronic acid can relieve the pain of metastatic bone tumors effectively with little adverse effects,It is acceptable and worth to used in clinic.
出处 《临床合理用药杂志》 2009年第2期7-8,共2页 Chinese Journal of Clinical Rational Drug Use
关键词 肿瘤 骨转移 疼痛 唑来膦酸 Metastatic bone tumors Pain Zoledronic acid
  • 相关文献

参考文献4

二级参考文献31

  • 1Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase Ⅲ, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol,2003,21 (16) :3150-3157.
  • 2Li EC, Davis LE. Zoledronic acid: a new parenteral bisphosphonate.Clin Ther, 2003,25 ( 11 ) :2669-2708.
  • 3Saad F. Treatment of bone complications in advanced prostate cancer:rationale for bisphosphonate use and results of a phase Ⅲ trial with zoledronic acid. Semin Oncol, 2002,29 (6 Suppl 21 ) : 19-27.
  • 4Bilston LE, Little DG, Smith NC, et al. Zoledronic acid improves the mechanical properties of normal and healing bone. Clin Biomech ( Bristol, Avon), 2002,17(9-10) : 716-718.
  • 5Rosen L, Harland SJ, Oosterlinck W. Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors. Am J Clin Oncol, 2002,25 (6 Suppl 1 ) :S19-24.
  • 6Lipton A, Small E, Saad E, et al. The new bisphosphonate, Zometa(zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest,2002,20( Suppl 2) :45-54.
  • 7Rosen LS,Gordon D,Kaminski M,et at. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 2003,98(8) :1735-1744.
  • 8Weinfurt KP, Castel LD, Li Y,et al. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care, 2004,42 ( 2 ) :164-175.
  • 9Rosen LS,Gordon DH,Dugan W Jr,et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer, 2004 , 100( 1 ) :36-43.
  • 10Harvey HA. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy. Semin Oncol, 2004,31 (6 Suppl 12) :23-30.

共引文献32

同被引文献33

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部